La Renon is a private-equity darling, there’s no two ways about it.

Over the last 10 years, half a dozen PE firms have put their chips on this private chronic-therapy pharma company, which, contrary to the French origin its name suggests, is based in Ahmedabad. 

Peak XV in 2015, A91 Partners in 2021, Chryscapital in 2024. Its list of investors is long and storied. And come 2025, there’s been a blitzkrieg of investments from Avendus in February, and Creador, Whiteoak, and Siguler Guff........

© The Ken